Page 1

SPAGO NANOMEDICAL AB Interim report January - June 2026 spago NANOMEDICAL APRIL - JUNE IN BRIEF • Net sales for the quarter amounted to KSEK 0 ( KSEK 81 ) The loss for the quarter amounted to KSEK -7,331 ( KSEK -6,964 ) • • Operating expenses for the quarter amounted to KSEK -8,418 ( KSEK -8,291 ) Earnings per share , before and after dilution , for the quarter amounted to SEK -0.01 ( SEK -0.02 ) Cash and cash equivalents at the end of the quarter amounted to KSEK 32,508 ( KSEK 18,517 ) JANUARI - JUNE IN BRIEF • Net sales for the half - year period amounted to KSEK 22 ( KSEK 419 ) • The loss for the half - year period amounted to KSEK -14,128 ( KSEK -14,399 ) Operating expenses for the half - year period amounted to KSEK -16,385 ( KSEK -17,255 ) Earnings per share , before and after dilution , for the half - year period amounted to SEK -0.02 ( SEK -0.04 ) SIGNIFICANT EVENTS DURING THE QUARTER • • • • The Data Monitoring Committee ( DMC ) of the Tumorad - 01 study declared that one of the primary endpoints , identifying the maximum tolerated dose , has been met and recommends that an additional two patients are enrolled at the dose level of 15 MBq / kg ( fractionated ) to provide a basis for defining a recommended phase II dose and completing the phase I part of the study . Significant visible tumor uptake of 177 Lu - SN201 has been observed in an additional patient with head and neck cancer , strengthening proof - of - concept for the Tumorad program . The Principal Investigator and Associate Professor Kim Taubman of St. Vincent's Hospital in Australia , presented the ongoing clinical phase I / lla study Tumorad - 01 with 177Lu - SN201 at the 56th Annual Scientific Meeting held by the Australian and New Zealand Society of Nuclear Medicine ( ANZSNM ) . The conference took place in Canberra on 15-17 May 2026 . At the Annual General Meeting , Alan Raffensperger was re - elected as Chairman of the Board , along with Mikael von Euler , Kari Grønås , and Nicklas Westerholm re - elected to the board , and Peter Lindell , Mikael Lönn , and Tiel Ridderstad newly elected to the board . The company completed a rights issue , which subscribed to approximately 93.1 percent and provided the company with approximately SEK 15.0 million before issue costs , intended to finance the completion of phase I of Tumorad - 01 and preparations for phase lla . SIGNIFICANT EVENTS AFTER THE QUARTER Nothing to report • Spago Nanomedical AB ( org . no . 556574–5048 ) - Interim report January - June , 2026